Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Genetic score is an objective and better measurement of inherited risk of prostate cancer than family history.

Sun J, Na R, Hsu FC, Zheng SL, Wiklund F, Condreay LD, Trent JM, Xu J.

Eur Urol. 2013 Mar;63(3):585-7. doi: 10.1016/j.eururo.2012.11.047. No abstract available.

2.

Genetic counseling for prostate cancer risk.

Nieder AM, Taneja SS, Zeegers MP, Ostrer H.

Clin Genet. 2003 Mar;63(3):169-76. Review.

PMID:
12694223
3.

The evolving role of familial history for prostate cancer.

Colloca G, Venturino A.

Acta Oncol. 2011 Jan;50(1):14-24. doi: 10.3109/0284186X.2010.521191. Review.

PMID:
20874046
4.

A review of targeted screening for prostate cancer: introducing the IMPACT study.

Mitra AV, Bancroft EK, Eeles RA; IMPACT Steering Committee and Collaborators..

BJU Int. 2007 Jun;99(6):1350-5. Review. No abstract available. Erratum in: BJU Int. 2007 Sep;100(3):718-9.

5.

Genetics of prostate cancer risk.

Pomerantz MM, Freedman ML.

Mt Sinai J Med. 2010 Nov-Dec;77(6):643-54. doi: 10.1002/msj.20222. Review.

PMID:
21105126
6.

How I Do It: Genetic counseling and genetic testing for inherited prostate cancer.

Giri VN, Gross L, Gomella LG, Hyatt C.

Can J Urol. 2016 Apr;23(2):8247-53. Review.

7.

Genetic and familial factors influencing breast, colon, prostate and lung cancers.

Stein QP, Flanagan JD.

S D Med. 2010;Spec No:16-22. Review.

PMID:
20397487
8.

Inherited predisposition to prostate cancer.

Verhage BA, Kiemeney LA.

Eur J Epidemiol. 2003;18(11):1027-36. Review.

PMID:
14620936
9.

Genetic cancer risk assessment.

Aiello-Laws L.

Semin Oncol Nurs. 2011 Feb;27(1):13-20. doi: 10.1016/j.soncn.2010.11.003. Review.

PMID:
21255709
10.

The family history as a tool to identify patients at risk for dilated cardiomyopathy.

Nauman D, Morales A, Cowan J, Dagua J, Hershberger RE.

Prog Cardiovasc Nurs. 2008 Winter;23(1):41-4. Review. No abstract available.

PMID:
18326985
11.

Analysis of family health history based risk assessment algorithms: classification and data requirements.

Ranade-Kharkar P, Del Fiol G, Williams JL, Hulse NC, Haug P.

Stud Health Technol Inform. 2013;192:1205. Review.

PMID:
23920979
12.

A genetics perspective on prostate cancer.

Lessick M, Katz A.

Urol Nurs. 2006 Dec;26(6):454-60. Review.

PMID:
17253080
13.

Genetic susceptibility to aggressive prostate cancer.

Ostrander EA, Kwon EM, Stanford JL.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1761-4. Review. No abstract available.

14.

[Clinical and basic aspects of familial prostate cancer].

Suzuki K, Matsui H, Ohtake N.

Gan To Kagaku Ryoho. 2013 Feb;40(2):159-63. Review. Japanese.

PMID:
23411953
15.

[Genetic susceptibility to prostate cancer].

Cussenot O, Cancel-Tassin G.

Med Sci (Paris). 2004 May;20(5):562-8. Review. French.

16.

The influence of family history on prostate cancer risk: implications for clinical management.

Madersbacher S, Alcaraz A, Emberton M, Hammerer P, Ponholzer A, Schröder FH, Tubaro A.

BJU Int. 2011 Mar;107(5):716-21. doi: 10.1111/j.1464-410X.2010.10024.x. Review.

17.

CYP1A1 polymorphisms and risk of prostate cancer: a meta-analysis.

Shaik AP, Jamil K, Das P.

Urol J. 2009 Spring;6(2):78-86. Review.

PMID:
19472123
18.

Perspective: prostate cancer susceptibility genes.

Simard J, Dumont M, Soucy P, Labrie F.

Endocrinology. 2002 Jun;143(6):2029-40. Review.

PMID:
12021166
19.

A review of genetic polymorphisms and prostate cancer risk.

Coughlin SS, Hall IJ.

Ann Epidemiol. 2002 Apr;12(3):182-96. Review.

PMID:
11897176
20.

THADA gene polymorphism and prostate cancer risk: a meta-analysis.

Zhao F, Xu Y, Yang K, Liu M, Wei D, Zhang Y, Shi X, Yang F, Wang X, Liang S, Zhao C, Chen X, Sun L, Zhu X, Wang N, Hui J, Zhang Y, Zhu L, Yang Y, Tang L, Wang J, Yang Z.

Oncol Res Treat. 2014;37(3):106-10. doi: 10.1159/000360206. Review. Erratum in: Oncol Res Treat. 2014;37(6):314.

PMID:
24685913
Items per page

Supplemental Content

Support Center